Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Ovid Therapeutics (OVID) had Return on Tangible Equity of -38.74% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.57M |
|
$-26.43M |
|
-- |
|
$0.57M |
|
$62.45M |
|
$-61.88M |
|
$35.45M |
|
$-26.43M |
|
$-26.43M |
|
$-26.43M |
|
$-26.43M |
|
$-26.43M |
|
$-26.43M |
|
$-61.88M |
|
$-61.27M |
|
70.91M |
|
70.91M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$55.94M |
|
$0.43M |
|
$36.23M |
|
$92.17M |
|
$10.52M |
|
$13.42M |
|
$13.42M |
|
$23.94M |
|
$68.23M |
|
$68.23M |
|
$68.23M |
|
71.01M |
|
| Cash Flow Statement Financials | |
$-55.96M |
|
$54.59M |
|
$0.62M |
|
$28.97M |
|
$28.23M |
|
$-0.74M |
|
$6.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.32 |
|
-- |
|
-- |
|
0.16 |
|
0.22 |
|
100.00% |
|
-10933.75% |
|
-10933.75% |
|
-10825.44% |
|
-4670.14% |
|
-4670.14% |
|
$-56.03M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-38.74% |
|
|
Return on Tangible Equity |
-38.74% |
-28.68% |
|
-32.38% |
|
$0.96 |
|
$-0.79 |
|
$-0.79 |
|